Aurobindo Pharma Ltd. (NSE: AUROPHARMA, BSE: 524804) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,05,150 Cr, it ranks #116 by market cap among the 6,197 Indian listed companies on FinBizNet, and #7 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,823.20 (as of 16 Nov 2026), the share price is 2.0% below its 52-week high of ₹1,859.90 and 64.8% above its 52-week low of ₹1,106.00. The share price is up 59.8% over one year and up 9.6% over three months.
| Current Price | ₹1,823.20 |
|---|---|
| Market Cap | ₹1,05,150 Cr |
| NSE Symbol | AUROPHARMA |
| BSE Code | 524804 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 30 |
| Return on Equity | 9.93% |
| Return on Assets | 5.95% |
| 52-Week Range | ₹1,106.00 – ₹1,859.90 |
| 1-Year Price Change | +59.8% |
| 3-Month Price Change | +9.6% |
| Beta (1Y) | 0.06 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.aurobindo.com |
| Revenue | ₹10,263 Cr |
|---|---|
| Net Profit | ₹1,124 Cr |
| Net Margin | 11.0% |
| EPS (Basic) | ₹19.57 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aurobindo Pharma Ltd. reported revenue of ₹10,263 Cr in Q2 FY27, up 23.9% from ₹8,286 Cr in Q2 FY26 and up 12.2% from ₹9,150 Cr in Q1 FY27. It posted a net profit of ₹1,124 Cr for the quarter, against a net profit of ₹848 Cr in Q2 FY26 (up 32.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹7,868 Cr (Q1 FY26) to ₹10,263 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹10,263 Cr | ₹1,124 Cr | 11.0% |
| Q1 FY27 | ₹9,150 Cr | ₹1,032 Cr | 11.3% |
| Q4 FY26 | ₹8,853 Cr | ₹921 Cr | 10.4% |
| Q3 FY26 | ₹8,646 Cr | ₹910 Cr | 10.5% |
| Q2 FY26 | ₹8,286 Cr | ₹848 Cr | 10.2% |
| Q1 FY26 | ₹7,868 Cr | ₹824 Cr | 10.5% |
| Q4 FY25 | ₹8,382 Cr | ₹903 Cr | 10.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 51.88% of Aurobindo Pharma Ltd.'s shares as of Sept 2026, against 51.82% in Sept 2025 (+0.06 percentage points). Delivery averaged 52.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
1. Bulk Drugs-This segment engages in manufacturing and marketing active pharmaceutical ingredients, generic pharmaceuticals, and related services. 2. Formulations-This segment manufactures semi-synthetic penicillins, and value added products, such as cephalsoporins, quinolones, macrolides, and other bulk actives. 3. Other Operations-This segment manufactures finished dosages mainly in the categories of gastro respiratory infection pain; cardio neuro diabetes psychiatry; AIDS; and analgesics, anti infectives, and cough and cold injectables. 4. Research & Development-This segment engages in trading and investing activities.
1. Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Glenmark Pharmaceuticals Limited | ₹75,556 Cr | 55.1 | 14.07% | ₹4,157 Cr | +45.7% |
Listed by market capitalisation. Ratios are shown for context only.
Aurobindo Pharma Ltd. is trading at ₹1,823.20, with a market capitalisation of ₹1,05,150 Cr.
Aurobindo Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Aurobindo Pharma Ltd. has a P/E of 30 and a return on equity of 9.93%.
Aurobindo Pharma Ltd. is listed on the NSE under the symbol AUROPHARMA and on the BSE under the scrip code 524804.
Aurobindo Pharma Ltd.'s share price is up 59.8% over one year and up 9.6% over three months. Its 52-week range is ₹1,106.00 to ₹1,859.90.
In Q2 FY27, Aurobindo Pharma Ltd. reported revenue of ₹10,263 Cr and net profit of ₹1,124 Cr, with basic EPS of ₹19.57 (consolidated, parsed from the company's exchange filing).
Aurobindo Pharma Ltd. reported revenue of ₹10,263 Cr in Q2 FY27, up 23.9% from ₹8,286 Cr in Q2 FY26 and up 12.2% from ₹9,150 Cr in Q1 FY27.
Promoters held 51.88% of Aurobindo Pharma Ltd.'s shares as of Sept 2026, against 51.82% in Sept 2025 (+0.06 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.